Issued on behalf of Avant Technologies Inc.

代表 Avant Technologies Inc. 发布。

Equity Insider

股权内幕

News Commentary

新闻评论

VANCOUVER, BC

加拿大温哥华

,

，

June 10, 2025

2025年6月10日

/PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a

/PRNewswire/ -- 政界和学术界的领袖们都在吹捧人工智能革命，赋能被称为智能医疗的前线。在

recent write-up

最近的撰写内容

in

在

Forbes

福布斯

, Prof.

，教授。

Nicos Savva

尼科斯·萨瓦

of the

的

London Business School

伦敦商学院

cited recent speeches from former British Prime Minister

引用了前英国首相最近的讲话

Tony Blair

托尼·布莱尔

, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from

，他坚称英国需要拥抱拥有AI医生和护士的未来，否则就有落后的风险。一份新的报告来自

Wolters Kluwer

威科集团

has

有

experts calling

专家呼叫

for more clarity around its use, adoption, and business strategy, because most healthcare organizations

为了更清楚地了解其使用、采用和商业策略，因为大多数医疗保健组织

aren't currently ready

目前还没有准备好

to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including

使用GenAI工具。但随着该领域实施的增加，创新者们也在迎来重大发展，包括

Avant Technologies, Inc.

前沿科技公司

(OTCQB:

(OTCQB:

AVAI

可用的

),

),

Renovaro Inc.

仁诺瓦罗公司

(NASDAQ:

（纳斯达克：

RENB

任播

),

),

Alphabet, Inc.

谷歌母公司

(NASDAQ:

（纳斯达克：

GOOG

谷歌

) (NASDAQ:

) （纳斯达克：

GOOGL

谷歌

),

),

Omada Health, Inc.

Omada Health公司

(NASDAQ:

（纳斯达克：

OMDA

OMDA

), and

)，以及

Amazon.com, Inc.

亚马逊公司

(NASDAQ:

（纳斯达克：

AMZN

亚马逊

).

）。

McKinsey's Global Institute

麦肯锡全球研究院

estimates Gen AI could unlock

估计通用人工智能可以解锁

$60–110 billion

600亿～1100亿美元

in annual value across pharma and medical products alone.

仅在制药和医疗产品领域的年度价值就达到。

Statista

Statista

now projects the global AI healthcare market will soar from

现在预计全球人工智能医疗市场将从

$11 billion

110亿美元

to

至

$188 billion

1880亿美元

by 2030

到2030年

.

。

Avant Technologies, Inc.

前沿科技公司

(OTCQB:

(OTCQB:

AVAI

可用性指标

) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of

）在其从人工智能孵化器向全栈医疗创新者演变的过程中刚刚迈出了重要的一步。今天，该公司宣布已签署了一份不具约束力的意向书，将收购 100% 的股份。

Ainnova Tech

艾诺瓦科技

, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through

，其合资伙伴以及Vision AI诊断平台的开发者。在收购之前，这两家公司通过以下方式共同运营：

Ai-nova Acquisition Corp (AAC)

艾诺瓦收购公司 (AAC)

, which holds

，其中包含

global licensing rights

全球授权权利

to

到

Ainnova's

艾诺瓦的

technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments.

技术组合，并作为Vision AI及所有未来设备部署的商业化引擎。

'We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally,' said

“我们认为，将两家公司合并将为股东带来巨大价值，它将简化我们技术推向市场的进程，并且在我们在全球推广我们的技术组合时，为客户和合作伙伴带来价值，”

Vinicio Vargas

维尼西奥·瓦尔加斯

, CEO at

，首席执行官 tại

Ainnova

艾诺瓦

and a member of the Board of Directors of

并且是董事会成员

AAC

高级音频编码（Advanced Audio Coding）

. 'We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare.'

“我们认为合资企业取得了成功，两家公司为了一个共同的目标都合作得很好，所以我们相信我们可以更加成功，将资源更有效地利用起来，成为一家公司，进一步推动人工智能在医疗保健领域的应用。”

Under the proposed agreement,

根据拟议协议，

Ainnova

艾诺瓦

would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled

将把所有未偿股权转入合并后的上市实体——在预定的日期前统一领导并消除结构复杂性。

FDA

食品药品监督管理局

pre-submission meeting

提交前会议

in July

在七月

.

。

While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of

虽然交易的最终条款仍在谈判中，但两家公司均表示，此次合并将简化商业化进程并加速推出

Ainnova's

艾诺瓦的

flagship Vision AI technology — a platform already in use across clinical sites in

旗舰版Vision AI技术——一个已经在临床站点广泛使用的平台

Latin America

拉丁美洲

for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from

用于糖尿病视网膜病变、心血管疾病和其他慢性病的早期检测。此举也表明了越来强的信心

Avant's

前卫的

leadership as they prepare to bring proprietary hardware into the mix.

他们准备将专有硬件引入市场之际的领导地位。

In parallel with the merger discussions,

与合并讨论同时进行，

Avant

之前

and

和

Ainnova

艾诺瓦

are entering the

正在进入

final prototyping stage

最终原型阶段

of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics.

低成本、自动化的视网膜成像设备——标志着这两家公司在推动人工智能早期诊断方面的共同努力可能迎来一个转折点。

The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel.

新设备设计为免提操作，并将成像数据直接输入到Vision AI平台中，从而在无需昂贵设备或训练有素的人员的情况下实现近乎即时的风险报告。

The companies say the camera, developed under their joint venture

这些公司表示，这款相机是根据他们的合资企业开发的

Ai-nova Acquisition Corp. (AAC)

艾诺瓦收购公司 (AAC)

, is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics.

，预计成本仅为传统眼底相机的一小部分。通过将经济实惠与自动化相结合，该设备可以扩大初级保健诊所和新兴市场供应商的筛查范围，这些供应商传统上因价格高昂而无法进行眼科诊断。

'The cost of a fundus camera has always been a barrier to entry in this market,' said Vargas. 'Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.'

“眼底相机的成本一直是进入这个市场的障碍，”瓦尔加斯说。“我们的低成本相机，只有市场上现有相机成本的一小部分，应该不仅能够让我们进入市场，还能占据很大的市场份额。”

Also in development are additional platform modules, including a

同时在开发中的还有额外的平台模块，包括一个

patented dementia detection

专利痴呆症检测

tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare.

结合了五分钟血液检测和人工智能训练算法的工具。尽管该技术仍在评估中，但核心平台不断扩大其覆盖范围和功能——从专注于视网膜的应用发展为更广泛的预测性医疗引擎。

'Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,' said Vargas in a

“我们的目标是以一种可及的方式创造早期疾病检测的未来，这样患者就可以在任何地方以低成本和便捷的方式进行预防性检查，”瓦加斯在采访中表示。

previous statement

上一声明

. 'We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.'.

“我们希望防止具有风险因素的患者发展出其他本可以避免的疾病，以免这些问题变得严重。为此，我们力求通过研发努力以及潜在的独家许可或收购，将新技术整合到我们的单一平台产品组合中。”

As the camera prototype nears completion,

随着摄像机原型接近完成，

Avant

之前

is positioning itself for

正在为自己定位

broader market entry

更广泛的市场进入

. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care.

虽然发布日期尚未公布，但该集成平台旨在减少诊断摩擦、加快转诊速度，并扩大对早期健康洞察的获取途径，尤其是在可负担性仍是医疗主要障碍而非创新的地区。

CONTINUED... Read this and more news for Avant Technologies at:

继续阅读... 请访问以下链接获取Avant Technologies的更多新闻：

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/

https://equity-insider.com/2025/03/21/解锁万亿美元人工智能市场-投资者需要知道什么/

Renovaro Inc.

仁诺瓦罗公司

(NASDAQ:

（纳斯达克：

RENB

任播

)

)

recently announced

最近宣布

a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure.

其知识产权组合的重大扩展，新近获批的美国专利涵盖了其人工智能驱动的药物发现和诊断基础设施。

'This patent is a strategic milestone for

“这项专利是一个战略里程碑

Renovaro

更新

,' said

，'说

David Weinstein

大卫·温斯坦

, CEO of

，首席执行官

Renovaro

更新中心

. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.'

“结合我们之前获得的专利，它构成了一个可扩展的、端到端人工智能药物发现和诊断平台的技术基础，并加强了我们在数据驱动治疗和临床洞察快速增长市场中的地位。”

The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics.

该专利保护将基因组、成像、临床和健康记录数据整合到一个标准化框架中以用于大规模预测分析的方法。这些功能专为分布式计算环境而构建，符合生物制药行业向实时、可扩展分析发展的趋势。

The development enhances .

开发增强了。

Renovaro's

雷诺瓦罗的

competitive positioning in data-driven therapeutics and clinical insight markets.

在数据驱动的治疗学和临床洞察市场中的竞争定位。

Alphabet, Inc.

字母表公司

(NASDAQ:

（纳斯达克：

GOOG

谷歌

) (NASDAQ:

) （纳斯达克：

GOOGL

谷歌

)

)

recently showcased

最近展示

its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where

它在2025年ASCO年会上展示了其在人工智能驱动的癌症研究领域的领导地位，其中

Ruth Porat

鲁思·波拉特

discussed

讨论过的

Alphabet's

字母表的

evolving role in early diagnosis and treatment.

在早期诊断和治疗中不断发展的角色。

'AI has greater potential than the internet, because it can augment human capabilities,' wrote

“人工智能比互联网有更大的潜力，因为它可以增强人类的能力，”

Ruth Porat

鲁思·波拉特

, President & Chief Investment Officer of

，总裁兼首席投资官

Alphabet

字母表

and

和

Google

谷歌

, quoting

，引用

Vint Cerf

温特·瑟夫

. 'It is a partner for all of you, for each of us.'

‘它是你们所有人的伙伴，是我们每个人的伙伴。’

Porat highlighted

波拉特强调了

Google's

谷歌的

success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery..

AlphaFold的成功解决了长达数十年的蛋白质折叠问题，从而加速了癌症药物的发现。她还提到了该公司的人工智能辅助病理工具，这些工具将诊断时间缩短了一半，并提高了对微小转移灶的检测能力。从可扩展的糖尿病视网膜病变筛查到用于临床工作流程的生成式人工智能，她将人工智能描述为医疗保健服务中的变革性力量。

Omada Health, Inc.

欧姆达健康公司

(NASDAQ:

（纳斯达克：

OMDA

OMDA

) entered the public markets with a

) 进入了公共市场，伴随着

strong debut

强劲的首秀

, raising

，提高

$150 million

1.5亿美元

and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members.

首个交易日收盘时较IPO价格上涨了21%。该公司为糖尿病、高血压和肥胖症等慢性病提供人工智能增强型虚拟护理，服务超过67.9万名活跃会员。

In May, prior to the IPO,

在五月份，首次公开募股之前，

Omada

欧姆达

introduced

引入

Nutritional Intelligence

营养智能

, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for

，这是一种由OmadaSpark驱动的新会员体验——OmadaSpark是一个在临床访问之间提供个性化、基于证据的营养辅导的人工智能代理。随着需求的增加

GLP-1

GLP-1

medications,

药物，

Omada

欧麦达

is positioning its human-plus-AI model as essential to long-term metabolic health.

将其人类加人工智能模型定位为长期代谢健康的关键。

'We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food,' said

“我们认为，市场对于以行为科学为支撑的实时教育支持有着明确的需求，这可以改善人们对食物的心态和行为，”

Wei-Li Shao

邵伟力

, President at

，总裁在

Omada Health

欧姆达健康

. 'To meet the needs of our customers and members,

. ‘为了满足我们客户和会员的需求，

Omada

Omada

fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes.'

微调了其方法，以提供经过临床输入和专业知识训练的AI工具，与人类护理团队合作，帮助成员改善健康和经济成果。

Amazon.com, Inc.

亚马逊公司

(NASDAQ:

（纳斯达克：

AMZN

亚马逊

) continues to scale its digital health footprint via

)继续通过以下方式扩大其数字健康足迹

Amazon Web Services (AWS)

亚马逊网络服务 (AWS)

, which

，哪一个

recently brought

最近带来

its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using

将其HealthLake平台扩展到欧盟的都柏林地区。此举使医院和保险公司能够利用该平台统一分散的患者数据。

FHIR

FHIR

standards, while running AI-driven analytics and maintaining full data residency compliance.

标准，同时运行人工智能驱动的分析并保持完全的数据驻留合规性。

'I'm excited about AWS HealthLake launch in EU Region,' said

“我对AWS HealthLake在欧盟地区的推出感到兴奋，”他说。

Ramon Postulart

拉蒙·波斯图拉特

, CTO at

，首席技术官 at

Adapcare

适配关怀

. '

。'

AWS

亚马逊云服务

HealthLake is a key

HealthLake 是一个关键

AWS

亚马逊云服务

healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in

医疗保健服务帮助我们实现与所支持的70多家护理机构和60,000名健康专业人士的现代化互操作性

the Netherlands

荷兰

. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination.'

“通过转向这项服务，我们正在解锁更丰富、标准化的健康数据，并利用 HealthLake 的全托管功能来构建更智能、支持 AI 的护理规划和协调工具。”

HealthLake now serves as the engine behind personalized care tools in development across

HealthLake现在是正在开发的个性化护理工具背后的引擎

Ireland

爱尔兰

,

，

the Netherlands

荷兰

, and

，以及

Finland

芬兰

.

。

AWS

亚马逊云服务

also hosted its

还举办了其

Health Data & AI Day in

健康数据与人工智能日

Dublin

都柏林

to promote cross-border health data innovation and the European Health Data Space initiative.

促进跨境健康数据创新和欧洲健康数据空间倡议。

Source:

源：

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/

https://equity-insider.com/2025/03/21/解锁万亿美元人工智能市场-投资者需要知道什么/

CONTACT:

联系人：

Equity Insider

股权内幕

info@equity-insider.com

info@equity-insider.com

(604) 265-2873

(604) 265-2873

DISCLAIMER:

免责声明：

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision.

本出版物中的任何内容均不应被视为个性化的财务建议。我们并未根据证券法获得处理您特定财务状况的许可。我们员工与您的任何沟通都不应被视为个性化的财务建议。在做出任何投资决定之前，请咨询持有执照的财务顾问。

This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

这是一则付费广告，既不是购买或出售任何证券的要约，也不是建议。我们未持有任何投资许可证，因此没有资格提供投资建议。本报告或电子邮件中的内容并非针对任何个人的具体情况而提供。

Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock.

Equity Insider是Market IQ Media Group, Inc.（“MIQ”）的全资子公司。MIQ已直接从Avant Technologies Inc.收取了广告和数字媒体费用。可能存在持有Avant Technologies Inc.股票的第三方，他们可能会抛售其股票，这可能对股票价格产生负面影响。

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc.

这种补偿构成了我们对公司概况进行客观沟通的能力上的利益冲突。由于这一冲突，强烈建议个人不要将本出版物作为任何投资决策的依据。MIQ的所有者/运营商持有Avant Technologies Inc.的股份。

which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved b.

这些股份是在公开市场上购买的。MIQ保留在任何时候买卖Avant Technologies Inc.股票的权利，并将在无进一步通知的情况下进行买卖。我们还预计会有更多的补偿，作为持续的数字媒体推广工作以提高公司知名度，虽然不会另行通知，但请知悉本免责声明即为通知：MIQ发布的一切资料均已获得批准。

Logo -

标志 -

https://mma.prnewswire.com/media/2644233/5362794/Equity_Insider_Logo.jpg

https://mma.prnewswire.com/media/2644233/5362794/Equity_Insider_Logo.jpg

SOURCE Equity Insider

来源：Equity Insider

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用